Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction
Authors:
- Yingzhi BiYBYingzhi Bi
- Patrick StoyPSPatrick Stoy
- Leonard AdamLALeonard Adam
- Bin HeBHBin He
- John KrupinskiJKJohn Krupinski
- Diane NormandinDNDiane Normandin
- Ron PongracRPRon Pongrac
- Laurie SeligerLSLaurie Seliger
- Andrew WatsonAWAndrew Watson
- John E MacorJMJohn E Macor
- 1 March 2004
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (6) , 1577-1580
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The discovery of novel, potent and selective PDE5 inhibitorsBioorganic & Medicinal Chemistry Letters, 2001
- Substituted Pyrazolopyridines as Potent and Selective PDE5 Inhibitors: Potential Agents for Treatment of Erectile DysfunctionJournal of Medicinal Chemistry, 2001
- Phosphodiesterase 5 inhibitors and nitrergic transmission—from zaprinast to sildenafilEuropean Journal of Pharmacology, 2001
- Optimization of Substituted N-3-Benzylimidazoquinazolinone Sulfonamides as Potent and Selective PDE5 InhibitorsJournal of Medicinal Chemistry, 2000
- N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile DysfunctionJournal of Medicinal Chemistry, 2000
- 4-Benzylamino-1-chloro-6-substituted Phthalazines: Synthesis and Inhibitory Activity toward Phosphodiesterase 5Journal of Medicinal Chemistry, 1998
- Phosphodiesterase inhibitors in the treatment of erectile dysfunctionDrugs of Today, 1998
- The role of phosphodiesterase inhibitors in impotenceExpert Opinion on Investigational Drugs, 1997
- SildenafilDrugs of the Future, 1997
- Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunctionBioorganic & Medicinal Chemistry Letters, 1996